Alvaro Lassaletta

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8560675/publications.pdf

Version: 2024-02-01

50 papers

2,768 citations

20 h-index 223800 46 g-index

55 all docs 55 docs citations

55 times ranked 4047 citing authors

#	Article	IF	CITATIONS
1	Prognostic factors for patients with relapsed central nervous system nongerminomatous germ cell tumors. Pediatric Blood and Cancer, 2022, 69, e29365.	1.5	3
2	Methotrexateâ€induced strokeâ€like neurotoxicity: Case report, 8Âyears of experience, and literature review. Pediatric Blood and Cancer, 2022, 69, e29627.	1.5	2
3	Intracranial desmoplastic small round cell tumor after childhood acute myeloid leukemia treated with metronomic oral cyclophosphamide. Pediatric Blood and Cancer, 2022, 69, e29687.	1.5	O
4	Real-world data for pediatric medulloblastoma: can we improve outcomes?. European Journal of Pediatrics, 2021, 180, 127-136.	2.7	8
5	Evaluation of the Pediatric Neuro-Oncology Resources Available in Chile. JCO Global Oncology, 2021, 7, 425-434.	1.8	3
6	Followâ€up evaluation of a webâ€based pediatric brain tumor board in Latin America. Pediatric Blood and Cancer, 2021, 68, e29073.	1.5	7
7	Survival Benefit for Individuals With Constitutional Mismatch Repair Deficiency Undergoing Surveillance. Journal of Clinical Oncology, 2021, 39, 2779-2790.	1.6	40
8	Treatment of radiation-induced myelopathy with bevacizumab. Clinical and Translational Oncology, 2020, 22, 957-960.	2.4	4
9	Gemcitabine, paclitaxel, and oxaliplatin (GEMPOX) in the treatment of relapsed/refractory intracranial nongerminomatous germ cell tumors. Pediatric Blood and Cancer, 2020, 67, e28089.	1.5	7
10	Neuropsychological Profile in Children with Posterior Fossa Tumors with or Without Postoperative Cerebellar Mutism Syndrome (CMS). Cerebellum, 2020, 19, 78-88.	2.5	32
11	Can monitoring asparaginase activity help us to manage toxicity in pediatric acute lymphoblastic leukemia?. Leukemia and Lymphoma, 2020, 61, 990-992.	1.3	2
12	Initial report on Spanish pediatric oncologic, hematologic, and post stem cell transplantation patients during SARSâ€CoVâ€2 pandemic. Pediatric Blood and Cancer, 2020, 67, e28557.	1.5	31
13	Helpful Criteria When Implementing NGS Panels in Childhood Lymphoblastic Leukemia. Journal of Personalized Medicine, 2020, 10, 244.	2.5	1
14	Genetic and Immune Changes Associated with Disease Progression under the Pressure of Oncolytic Therapy in A Neuroblastoma Outlier Patient. Cancers, 2020, 12, 1104.	3.7	12
15	Integrated Molecular and Clinical Analysis of 1,000 Pediatric Low-Grade Gliomas. Cancer Cell, 2020, 37, 569-583.e5.	16.8	244
16	Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas. Nature Communications, 2019, 10, 4343.	12.8	200
17	Improving the quality of care in the molecular era for children and adolescents with medulloblastoma. Clinical and Translational Oncology, 2019, 21, 1687-1698.	2.4	4
18	Survival and functional outcomes of molecularly defined childhood posterior fossa ependymoma: Cure at a cost. Cancer, 2019, 125, 1867-1876.	4.1	49

#	Article	IF	Citations
19	The Latin American Brain Tumor Board teleconference: results of a web-based survey to evaluate participant experience utilizing this resource. Child's Nervous System, 2019, 35, 257-265.	1.1	13
20	Old drugs still work! Oral etoposide in a relapsed medulloblastoma. Child's Nervous System, 2019, 35, 865-869.	1.1	3
21	Volumetric assessment of tumor size changes in pediatric low-grade gliomas: feasibility and comparison with linear measurements. Neuroradiology, 2018, 60, 427-436.	2.2	22
22	Reirradiation in patients with diffuse intrinsic pontine gliomas: The Canadian experience. Pediatric Blood and Cancer, 2018, 65, e26988.	1.5	51
23	DEV-14. IMPACT OF A LATIN AMERICA-WIDE TELECONFERENCED BRAIN TUMOR BOARD. Neuro-Oncology, 2018, 20, i47-i48.	1.2	4
24	LGG-60. THE GENETIC LANDSCAPE OF PEDIATRIC LOW-GRADE GLIOMAS: INCIDENCE, PROGNOSIS AND RESPONSE TO THERAPY. Neuro-Oncology, 2018, 20, i117-i117.	1.2	1
25	Medulloblastoma in infants: the never-ending challenge. Lancet Oncology, The, 2018, 19, 720-721.	10.7	7
26	Second re-irradiation for DIPG progression, re-considering "old strategies―with new approaches. Child's Nervous System, 2017, 33, 849-852.	1.1	14
27	Multiplex Detection of Pediatric Low-Grade Glioma Signature Fusion Transcripts and Duplications Using the NanoString nCounter System. Journal of Neuropathology and Experimental Neurology, 2017, 76, 562-570.	1.7	39
28	Intertumoral Heterogeneity within Medulloblastoma Subgroups. Cancer Cell, 2017, 31, 737-754.e6.	16.8	836
29	Isolated optic nerve gliomas: a multicenter historical cohort study. Journal of Neurosurgery: Pediatrics, 2017, 20, 549-555.	1.3	17
30	Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas. Journal of Clinical Oncology, 2017, 35, 2934-2941.	1.6	232
31	Molecular alterations to predict survival and response to chemotherapy of pediatric low-grade glioma Journal of Clinical Oncology, 2017, 35, 10503-10503.	1.6	O
32	HG-37SECOND RE-IRRADIATION FOR DIPG PROGRESSION, RE-CONSIDERING "OLD STRATEGIES―WITH NEW APPROACHES. Neuro-Oncology, 2016, 18, iii55.4-iii56.	1.2	1
33	CMS-03RISK FACTORS FOR LONG TERM SPEECH DEFICITS IN CHILDREN WITH CEREBELLAR MUTISM SYNDROME. Neuro-Oncology, 2016, 18, iii16.3-iii16.	1.2	O
34	No correlation between NF1 mutation position and risk of optic pathway glioma in 77 unrelated NF1 patients. Human Genetics, 2016, 135, 469-475.	3.8	29
35	An integrative molecular and genomic analysis of pediatric hemispheric low-grade gliomas: an update. Child's Nervous System, 2016, 32, 1789-1797.	1.1	26
36	Phase II Weekly Vinblastine for Chemotherapy-NaÃ-ve Children With Progressive Low-Grade Glioma: A Canadian Pediatric Brain Tumor Consortium Study. Journal of Clinical Oncology, 2016, 34, 3537-3543.	1.6	157

3

#	Article	IF	Citations
37	Profound clinical and radiological response to BRAF inhibition in a 2â€monthâ€old diencephalic child with hypothalamic/chiasmatic glioma. Pediatric Blood and Cancer, 2016, 63, 2038-2041.	1.5	57
38	LG-19IMMUNOHISTOCHEMISTRY IS HIGHLY SENSITIVE AND SPECIFIC FOR THE DETECTION OF BRAF V600E STATUS IN PEDIATRIC LOW-GRADE GLIOMA. Neuro-Oncology, 2016, 18, iii82.3-iii82.	1.2	1
39	Medulloblastoma in adults: they're not just big kids. Neuro-Oncology, 2016, 18, 895-897.	1.2	23
40	Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis. Journal of Clinical Oncology, 2016, 34, 2468-2477.	1.6	160
41	Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. Lancet Oncology, The, 2016, 17, 484-495.	10.7	274
42	Relationship of BRAF V600E and associated secondary mutations on survival rate and response to conventional therapies in childhood low-grade glioma Journal of Clinical Oncology, 2016, 34, 10509-10509.	1.6	3
43	Imaging of metastatic medulloblastoma in the molecular era Journal of Clinical Oncology, 2016, 34, e22003-e22003.	1.6	0
44	Functional and neuropsychological late outcomes in posterior fossa tumors in children. Child's Nervous System, 2015, 31, 1877-1890.	1.1	76
45	Outcome of neurofibromatosis type 1 patients treated with first line vinblastine for optic pathway gliomas: A Canadian multicenter study Journal of Clinical Oncology, 2015, 33, 2019-2019.	1.6	1
46	Efficacy and safety of liposomal cytarabine in children with primary CNS tumours with leptomeningeal involvement. Clinical and Translational Oncology, 2012, 14, 280-286.	2.4	10
47	A Persistent epidural mass in a child with Bâ€lineage ALL. Pediatric Blood and Cancer, 2010, 55, 727-729.	1.5	4
48	Intrathecal liposomal cytarabine in children under 4Âyears with malignant brain tumors. Journal of Neuro-Oncology, 2009, 95, 65-69.	2.9	22
49	Successful treatment of intracranial ependymoma with leptomeningeal spread with systemic chemotherapy and intrathecal liposomal cytarabine in a two-year-old child. Journal of Neuro-Oncology, 2007, 83, 303-306.	2.9	22
50	Reversal of an Antihistamine-Induced Coma With Flumazenil. Pediatric Emergency Care, 2004, 20, 319-320.	0.9	14